The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Feature|Videos|November 24, 2025
How ten23 health is Advancing Patient-Centric Drug Delivery
Author(s)Prof. Dr. Hanns-Christian Mahler, ten23 health
Key Takeaways
- Gain leadership and innovation insights from CEO of the Year finalist at 2025 CPHI Pharma Awards, Prof. Dr. Mahler Hanns-Christian, who serves as CEO and co-founder of ten23 health.
- Understand the role of patient-centric design in drug delivery.
Watch this interview and learn how advances in patient-centric drug delivery are transforming ten23 health's development strategies as a next-generation CDMO.
CEO of the Year finalist at 2025 CPHI Pharma Awards, Prof. Dr. Mahler Hanns-Christian, who serves as CEO and co-founder of ten23 health, explains how ten23 health is helping shape the future of patient-centric drug delivery systems and the evolving expectations of modern CDMOs. He shares how industry limitations—particularly around flexibility, innovation, and patient-focused design—motivated him to co-found the company and build a new model for sterile drug product development and manufacturing.
Prof. Dr. Hanns-Christian comments on the growing demand for subcutaneous and self-injection therapies, highlighting why ease of use, patient comfort, and real-world administration are becoming central considerations in formulation and device design. He also explains how CDMOs can better support pharma partners by integrating delivery-system thinking early in development, strengthening supply chain reliability, and offering high-quality testing and sterile manufacturing capabilities at scale.
Sustainability is another major theme of the conversation. He outlines how next-generation CDMOs can embed responsible operations, energy efficiency, and waste reduction into everyday decision-making—advancing both environmental goals and long-term business resilience.
Looking ahead, Prof. Dr. Hanns-Christian shares what excites him most about the future: expanded manufacturing capacity, continued innovation in patient-centric delivery, and new opportunities to elevate quality, reliability, and patient outcomes across the drug product lifecycle.
Related to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.